BOSTON--()--Conditas Biotechnology Group, LLC, a boutique firm that represents on- and off-shore Contract Research Organizations (CROs) and service providers, connecting them to customers in academia and the biotechnology and pharmaceutical industries, has signed an exclusive agreement with SYN|thesis med chem Pty Ltd.
“As 2011 comes to a close, external research directors and sourcing groups are searching for service expertise and capacity at a great value for their 2012-2013 projects and programs. Conditas looks forward to connecting academic research institutes, biotechnology firms, and pharmaceutical companies with SYN|thesis’ excellent products and services.”
Conditas will represent the Melbourne and Shanghai based company as its agent for business development and sales of services in the United States.
To kick off the relationship, Conditas and SYN|thesis med chem are offering significant cost savings for new customers who initiate contracts before the end of January 2012.
Leland L. Johnson, Jr. Founder and Principal at The Conditas Group, commented, “SYN|thesis is not just an efficient and cost-effective provider of synthetic chemistry resources, but it also supplies medicinal chemistry services at a superb value with a wealth of drug discovery experience. This new partnership broadens our offerings across the biology and chemistry spectrum and allows us to give our customers a more expansive suite of services.”
Dr. Xian Bu, Founder and Managing Director of SYN|thesis med chem said, “We are pleased to be working with Conditas. Leveraging their relationship-based approach to business development with a focus in the United States will help us achieve our strategic goals of building a powerful presence there in the coming years. With local BD presence we can also provide better service to our US-based clients.”
Mr. Johnson added, “As 2011 comes to a close, external research directors and sourcing groups are searching for service expertise and capacity at a great value for their 2012-2013 projects and programs. Conditas looks forward to connecting academic research institutes, biotechnology firms, and pharmaceutical companies with SYN|thesis’ excellent products and services.”
About Conditas Biotechnology Group, LLC
Conditas Biotechnology Group, LLC is a boutique firm representing on- and off-shore Contract Research Organizations (CROs) and service providers in the biotechnology and pharmaceutical industry to their current and potential future customers from academia, biotech, and pharma. Based in Brookline, Massachusetts, their client CROs include experts in all niches of discovery, purification, development, commercialization and project management, including areas within small molecule (medicinal chemistry) and biomolecular research and development (proteins, antibodies, bioconjugates), in vitro and in vivo testing of compound characteristics and safety profiles, DNA sequencing (genomics), and the requisite management of such multi-disciplinary projects and programs.
About SYN|thesis Med Chem Pty Ltd
SYN|thesis med chem Pty Ltd is a leading medicinal chemistry Contract Research Organisation that provides important research tools, reagents and contract research services to facilitate and accelerate the drug discovery process. Based in Melbourne, Australia and Shanghai, PRC, their customers include academic research institutions, pharmaceutical companies and biotechnology companies around the world, all of which participate in the discovery of new drugs. As well as providing comprehensive medicinal chemistry services, SYN|thesis provides computational chemistry services through its subsidiary, Qubist Molecular Design. Qubist employs a quantum mechanical approach to delivering improved in silico screening and drug design.
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
